NewAmsterdam Reports $17.4 Million Quarterly Loss as Drug Advances
The company reported higher quarterly revenue, European approvals for two obicetrapib products and plans for key trial updates.
Makkler Newsroom · Nov 4, 08:52 PM · 1 min read
NewAmsterdam Pharma Company N.V. NAMS
NASDAQHealth TechnologyUnited States
$20.14+0.17 (+0.85%)
Market closed· · USD · Data may be delayed
- Day's range
- 19.4920.61
- 52-week range
- 17.9042.21
Financial health
– / 5
Analyst view · 17 firms
Buy16 buy · 1 hold · 0 sell
Avg. target $51.73 (+156.9%)
Prices may be delayed and are for informational purposes only - not investment advice.